Algenpantucel-L

Known as: Alpha (1,3) Galactosyltransferase Tumor Vaccine, Alpha-1,3-Galactosyltransferase-expressing Allogeneic Pancreatic Tumor Cell Vaccine, Alpha-Gal Pancreatic Cancer Vaccine 
A cancer vaccine comprised of irradiated allogeneic pancreatic cancer cells transfected to express murine alpha-1,3-galactosyltransferase with… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2016
01220112016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Pancreatic adenocarcinoma is the 4th leading cause of cancer death in the USA and the EU. A minority of patients presents with… (More)
Is this relevant?
Review
2016
Review
2016
Pancreatic adenocarcinoma is notoriously lethal, and despite improvements in systemic chemotherapy approaches bringing survival… (More)
Is this relevant?
Review
2015
Review
2015
Contemporary adjuvant therapy for pancreatic cancer patients following surgical resection includes chemotherapy and… (More)
Is this relevant?
Review
2014
Review
2014
BACKGROUND Despite recent progress with novel chemotherapy regimens, pancreatic ductal adenocarcinoma remains the fourth leading… (More)
  • figure 1
  • figure 2
Is this relevant?
2012
2012
Despite continued investigation, limited progress has been made in the adjuvant treatment of resected pancreatic cancer. Novel or… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2011
2011
236 Background: Pancreatic cancer portends a poor prognosis with ∼4% long-term survival. Among the estimated 20% of patients who… (More)
Is this relevant?
Review
2011
Review
2011
  • M. Saif
  • JOP : Journal of the pancreas
  • 2011
There is no consensus on what constitutes "standard" adjuvant therapy for pancreatic cancer. This controversy derives from… (More)
Is this relevant?